203 related articles for article (PubMed ID: 10391665)
1. Development of dapsone toxicity in patients with inflammatory dermatoses: activity of acetylation and hydroxylation of dapsone as risk factors.
Bluhm RE; Adedoyin A; McCarver DG; Branch RA
Clin Pharmacol Ther; 1999 Jun; 65(6):598-605. PubMed ID: 10391665
[TBL] [Abstract][Full Text] [Related]
2. The contribution of N-hydroxylation and acetylation to dapsone pharmacokinetics in normal subjects.
May DG; Porter JA; Uetrecht JP; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1990 Dec; 48(6):619-27. PubMed ID: 2249373
[TBL] [Abstract][Full Text] [Related]
3. Relationship between high incidence of adverse dapsone reactions and slow acetylate phenotype or low plasma/lymphocyte glutathione level.
Guo R; Thormann W; Lauterberg B
Chin Med J (Engl); 1996 Dec; 109(12):933-6. PubMed ID: 9275325
[TBL] [Abstract][Full Text] [Related]
4. Dapsone acetylation by human liver arylamine N-acetyltransferases and interaction with antiopportunistic infection drugs.
Palamanda JR; Hickman D; Ward A; Sim E; Romkes-Sparks M; Unadkat JD
Drug Metab Dispos; 1995 Apr; 23(4):473-7. PubMed ID: 7600914
[TBL] [Abstract][Full Text] [Related]
5. Monoacetyldapsone inhibition of dapsone N-hydroxylation by human and rat liver microsomes.
Irshaid Y; Adedoyin A; Lotze M; Branch RA
Drug Metab Dispos; 1994; 22(1):161-4. PubMed ID: 8149877
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the dapsone recovery ratio and the erythromycin breath test as in vivo probes of CYP3A activity in patients with rheumatoid arthritis receiving cyclosporine.
Stein CM; Kinirons MT; Pincus T; Wilkinson GR; Wood AJ
Clin Pharmacol Ther; 1996 Jan; 59(1):47-51. PubMed ID: 8549033
[TBL] [Abstract][Full Text] [Related]
7. Dapsone-induced photodermatitis in a patient with linear IgA dermatosis.
Stöckel S; Meurer M; Wozel G
Eur J Dermatol; 2001; 11(1):50-3. PubMed ID: 11174140
[TBL] [Abstract][Full Text] [Related]
8. Acetylator phenotype in Iraqi patients with atopic dermatitis.
Najim RA; Al-Waiz MM; Al-Razzuqi RA
Dermatol Online J; 2006 Dec; 12(7):1. PubMed ID: 17459287
[TBL] [Abstract][Full Text] [Related]
9. Acetylation of dapsone by human whole blood.
Irshaid YM; al-Hadidi HF; Abuirjeie MA; Rawashdeh NM; Gharaibeh NS
Int J Clin Pharmacol Ther Toxicol; 1993 Jan; 31(1):18-22. PubMed ID: 8444513
[TBL] [Abstract][Full Text] [Related]
10. The disposition of dapsone in cirrhosis.
May DG; Arns PA; Richards WO; Porter J; Ryder D; Fleming CM; Wilkinson GR; Branch RA
Clin Pharmacol Ther; 1992 Jun; 51(6):689-700. PubMed ID: 1611807
[TBL] [Abstract][Full Text] [Related]
11. Reassessment of dapsone as a marker of acetylator phenotypes.
Wiggan EB; Dennis S; Reele SB; Luke DR
Int J Clin Pharmacol Ther Toxicol; 1991 Jul; 29(7):262-8. PubMed ID: 1889912
[TBL] [Abstract][Full Text] [Related]
12. Influence of acetylator phenotype of the leprosy patient on the emergence of dapsone resistant leprosy.
Raj PP; Aschhoff M; Lilly L; Balakrishnan S
Indian J Lepr; 1988 Jul; 60(3):400-6. PubMed ID: 3058828
[TBL] [Abstract][Full Text] [Related]
13. Acetylator phenotype in Iraqi patients with systemic lupus erythematosus.
Najim RA; Farid YY; Samad TA; Shihab SA
East Mediterr Health J; 2005; 11(5-6):1003-8. PubMed ID: 16761671
[TBL] [Abstract][Full Text] [Related]
14. The effect of clarithromycin, fluconazole, and rifabutin on dapsone hydroxylamine formation in individuals with human immunodeficiency virus infection (AACTG 283).
Winter HR; Trapnell CB; Slattery JT; Jacobson M; Greenspan DL; Hooton TM; Unadkat JD
Clin Pharmacol Ther; 2004 Dec; 76(6):579-87. PubMed ID: 15592329
[TBL] [Abstract][Full Text] [Related]
15. Validation of the five-drug "Pittsburgh cocktail" approach for assessment of selective regulation of drug-metabolizing enzymes.
Frye RF; Matzke GR; Adedoyin A; Porter JA; Branch RA
Clin Pharmacol Ther; 1997 Oct; 62(4):365-76. PubMed ID: 9357387
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic profiles in rats after intravenous, oral, or dermal administration of dapsone.
Helton DR; Osborne DW; Pierson SK; Buonarati MH; Bethem RA
Drug Metab Dispos; 2000 Aug; 28(8):925-9. PubMed ID: 10901702
[TBL] [Abstract][Full Text] [Related]
17. A clinical trial on absorption and N-acetylation of oral and rectal mesalazine.
Dilger K; Trenk D; Rössle M; Cap M; Zähringer A; Wacheck V; Remmler C; Cascorbi I; Kreisel W; Novacek G
Eur J Clin Invest; 2007 Jul; 37(7):558-65. PubMed ID: 17576207
[TBL] [Abstract][Full Text] [Related]
18. Interactions of glucose-6-phosphate dehydrogenase deficiency with drug acetylation and hydroxylation reactions.
Magon AM; Leipzig RM; Zannoni VG; Brewer GJ
J Lab Clin Med; 1981 Jun; 97(6):764-70. PubMed ID: 7229511
[TBL] [Abstract][Full Text] [Related]
19. N-acetylation polymorphism of dapsone in a Japanese population.
Horai Y; Ishizaki T
Br J Clin Pharmacol; 1988 Apr; 25(4):487-94. PubMed ID: 3382590
[TBL] [Abstract][Full Text] [Related]
20. Dapsone and sulfapyridine.
Paniker U; Levine N
Dermatol Clin; 2001 Jan; 19(1):79-86, viii. PubMed ID: 11155588
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
